成人复发缓解型多发性硬化症何时开始使用疾病修正药物？
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?
作者信息
Alkhawajah Mona, Oger Joel
机构信息
Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2H5.
出版信息
Mult Scler Int. 2011;2011:724871. doi: 10.1155/2011/724871. Epub 2011 May 17.
Abstract
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
摘要
对于复发缓解型多发性硬化症患者，β-干扰素和醋酸格拉替雷是首批获得治疗许可的药物。本综述探讨一个主要问题：何时开始治疗？通过探究该疾病和治疗方法的独特特征，我们提出一种有助于决策过程的方法。
相似文献
1
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?成人复发缓解型多发性硬化症何时开始使用疾病修正药物？
Mult Scler Int. 2011;2011:724871. doi: 10.1155/2011/724871. Epub 2011 May 17.
2
Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.利妥昔单抗在复发性缓解型多发性硬化症成人患者中的应用：一项系统性文献回顾。
Curr Med Res Opin. 2020 May;36(5):809-826. doi: 10.1080/03007995.2020.1739009. Epub 2020 Mar 20.
3
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.真实世界中聚乙二醇干扰素 β-1a 与皮下干扰素 β-1a、那他珠单抗和特立氟胺治疗复发缓解型多发性硬化症患者的疗效的倾向评分比较。
Mult Scler Relat Disord. 2021 Jun;51:102935. doi: 10.1016/j.msard.2021.102935. Epub 2021 Apr 8.
4
Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.富马酸二甲酯作为多发性硬化症患者一线治疗的有效性——一项单中心真实世界观察性研究
Pol Merkur Lekarski. 2019 Dec 27;47(282):221-225.
5
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.干扰素β与醋酸格拉替雷治疗复发缓解型多发性硬化症的对比
Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.
6
[Immunomodulatory therapy in multiple sclerosis].[多发性硬化症的免疫调节治疗]
Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16.
7
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.复发缓解型多发性硬化症中250微克或500微克β-1b干扰素与20毫克醋酸格拉替雷的对比：一项前瞻性、随机、多中心研究
Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2.
8
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症患者接受那他珠单抗治疗第一年期间的白质扩散变化
AJNR Am J Neuroradiol. 2016 Jun;37(6):1030-7. doi: 10.3174/ajnr.A4690. Epub 2016 Mar 10.
9
Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.与肿瘤坏死因子-α 相比，复发缓解型多发性硬化症患者血清白细胞介素-17水平的变化与疾病改善治疗相关。
Scand J Clin Lab Invest. 2017 Jul;77(4):283-288. doi: 10.1080/00365513.2017.1303843. Epub 2017 Mar 20.
10
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.皮下注射干扰素β-1a与醋酸格拉替雷治疗复发型多发性硬化症的比较（复发型多发性硬化症中重组人干扰素β-1a对比醋酸格拉替雷[REGARD]研究）：一项多中心、随机、平行、开放标签试验。
Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.
引用本文的文献
1
Digital Twins for Multiple Sclerosis.数字孪生在多发性硬化症中的应用。
Front Immunol. 2021 May 3;12:669811. doi: 10.3389/fimmu.2021.669811. eCollection 2021.
2
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.监测和管理接受阿仑单抗治疗的多发性硬化症患者的自身免疫：实用建议。
J Neurol. 2018 Nov;265(11):2494-2505. doi: 10.1007/s00415-018-8822-y. Epub 2018 Mar 10.
3
Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis.雪上加霜的是：多发性硬化症中的胃肠道症状和综合征。
Mult Scler Int. 2013;2013:319201. doi: 10.1155/2013/319201. Epub 2013 Sep 17.
4
Anorectal dysfunction in multiple sclerosis: a systematic review.多发性硬化症中的肛门直肠功能障碍：一项系统综述。
ISRN Neurol. 2012;2012:376023. doi: 10.5402/2012/376023. Epub 2012 Jul 29.
本文引用的文献
1
Current and emerging multiple sclerosis therapeutics.当前及新出现的多发性硬化症治疗方法。
Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):58-77. doi: 10.1212/01.CON.0000389934.84660.ec.
2
How long can you keep working with benign multiple sclerosis?患有良性多发性硬化症，你能工作多久？
J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):78-82. doi: 10.1136/jnnp.2010.210732. Epub 2010 Aug 27.
3
Cervical cord and brain grey matter atrophy independently associate with long-term MS disability.颈髓和脑灰质萎缩分别与多发性硬化症的长期残疾相关。
J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):471-2. doi: 10.1136/jnnp.2010.205021. Epub 2010 Aug 14.
4
Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.醋酸格拉替雷：在复发缓解型多发性硬化和延缓临床确诊多发性硬化发病中的应用评价。
Drugs. 2010 Aug 20;70(12):1545-77. doi: 10.2165/11204560-000000000-00000.
5
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.妊娠期醋酸格拉替雷暴露：初步安全性和出生结局。
J Neurol. 2010 Dec;257(12):2020-3. doi: 10.1007/s00415-010-5652-y. Epub 2010 Jul 13.
6
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.复发缓解型多发性硬化症临床试验中的残疾进展：八年随访
Arch Neurol. 2010 Nov;67(11):1329-35. doi: 10.1001/archneurol.2010.150. Epub 2010 Jul 12.
7
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.多发性硬化症中干扰素-β治疗的中和抗体数据的临床应用建议。
Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.
8
Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach.用于多发性硬化症 EDSS 恶化的替代终点。一种荟萃分析方法。
Neurology. 2010 Jul 27;75(4):302-9. doi: 10.1212/WNL.0b013e3181ea15aa. Epub 2010 Jun 23.
9
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.全球依从性项目（GAP）：一项关于复发缓解型多发性硬化症患者对疾病修正治疗依从性的多中心观察性研究。
Eur J Neurol. 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x.
10
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.多发性硬化症的自然病史：基于地理的研究 10：复发和长期残疾。
Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.
Zotero 插件